Journal of Cardio-diabetes and metabolic disorders,
Journal Year:
2023,
Volume and Issue:
3(2), P. 21 - 29
Published: July 1, 2023
Abstract
Diabetes
mellitus
is
one
of
the
most
prevalent
chronic
diseases
that
affect
a
significant
portion
“Golden-agers”
worldwide.
With
globally
rising
elderly
population
and
increasing
life
expectancy,
prevalence
diabetes
among
older
adults
expected
to
rise,
leading
morbidity
mortality
them
along
with
substantial
healthcare
burden.
The
type
2
(T2DM)
increases
age
extent
almost
half
diagnosed
diabetic
patients
are
now
above
65
years
age.
In
India,
overall
was
found
be
between
12%
20%
which
significantly
higher
in
urban
areas
than
rural.
etiology
T2DM
highly
diverse
but
mostly
associated
various
degrees
essential
insulin
resistance,
dysfunction
pancreatic
β-cell,
surplus
fat
accumulation,
loss
muscle
mass.
geriatric
population,
outline
management
has
moved
from
predominantly
glucose-lowering
approach
focused
complications-centric
approach,
aimed
at
preventing
mainly
short-term
long-term
complications
diabetes,
correcting
metabolic
abnormalities
managing
other
comorbidities
may
complicate
diabetes.
poses
unique
challenges
due
complex
interplay
aging,
comorbidities,
polypharmacy,
altered
physiological
responses
glucose
metabolism
necessitate
individualized
approaches.
Also,
presence
cognitive
decline,
frailty,
functional
impairment,
lack
familial
social
support,
varied
psychological
issues
further
raised
plasma
glucose.
This
review
aims
provide
an
in-depth
understanding
comprehensive
elderly,
focusing
on
critical
aspects
such
as
diagnosis,
treatment
strategies,
monitoring,
complications.
International Journal of Cardiology Cardiovascular Risk and Prevention,
Journal Year:
2024,
Volume and Issue:
23, P. 200326 - 200326
Published: Aug. 24, 2024
Heart
Failure
(HF)
and
Diabetes
Mellitus
(DM)
often
coexist,
each
condition
independently
increases
the
likelihood
of
developing
other.
While
there
has
been
concern
regarding
increasing
burden
disease
for
both
conditions
individually
over
last
decade,
a
comprehensive
examination
mortality
trends
demographic
regional
disparities
needs
to
be
thoroughly
explored
in
United
States
(US).
Journal of Diabetes Investigation,
Journal Year:
2024,
Volume and Issue:
15(10), P. 1347 - 1354
Published: Aug. 8, 2024
ABSTRACT
Advances
in
diabetes
medication
and
population
aging
are
lengthening
the
lifespans
of
people
with
mellitus
(DM).
Older
patients
often
have
multimorbidity
tend
to
polypharmacy.
In
addition,
is
associated
frailty,
functional
decline,
cognitive
impairment,
geriatric
syndrome.
Although
numbers
dementia,
disability,
and/or
increasing
worldwide,
accumulated
evidence
on
safe
effective
treatment
these
populations
remains
insufficient.
patients,
especially
those
older
than
75
years
old,
underrepresented
randomized
controlled
trials
various
effects,
resulting
limited
clinical
for
this
population.
Therefore,
a
deeper
understanding
characteristics
essential
tailor
management
strategies
their
needs.
The
guidelines
several
academic
societies
begun
recognize
importance
relaxing
glycemic
control
targets
prevent
severe
hypoglycemia
maintain
quality
life.
However,
levels
thus
far
based
expert
consensus
rather
robust
evidence.
There
an
urgent
need
personalized
adults
that
considers
function
strives
high
life
through
medical
treatment.
accompanied
by
require
special
considerations
liaison
both
carers
social
resources.
Metabolites,
Journal Year:
2025,
Volume and Issue:
15(1), P. 49 - 49
Published: Jan. 14, 2025
Background:
Frailty
is
an
increasingly
recognised
complication
of
diabetes
in
older
people
and
should
be
taken
into
consideration
management
plans,
including
the
use
new
therapies
sodium
glucose
cotransporter-2
(SGLT-2)
inhibitors
glucagon
like
peptide-1
receptor
agonists
(GLP-1RA).
The
frailty
syndrome
appears
to
span
across
a
spectrum,
from
sarcopenic
obese
phenotype
at
one
end,
characterised
by
obesity,
insulin
resistance,
prevalent
cardiovascular
risk
factors,
anorexic
malnourished
other
significant
weight
loss,
reduced
less
factors.
Therefore,
may
not
suitable
for
every
frail
individual
with
diabetes.
Objectives:
To
review
characteristics
who
benefit
SGLT-2
or
GLP-1RA.
Methods:
A
narrative
studies
investigating
benefits
GLP-1RA
Results:
current
evidence
indirect,
literature
suggests
that
are
effective
proportional
severity
frailty.
However,
patients
described
benefited
such
therapy
appeared
either
overweight
obese,
have
higher
prevalence
unfavourable
metabolism
factors
as
dyslipidaemia,
gout,
hypertension
compared
non-frail
subjects.
They
also
established
disease
individuals.
In
absolute
terms,
their
baseline
meant
they
most
therapy.
this
group
fulfil
criteria
phenotype,
which
likely
due
metabolic
profile
phenotype.
There
no
suggest
underrepresented
totally
excluded
these
studies,
living
care
homes.
This
intolerant
its
associated
inducing
further
dehydration,
hypotension.
Conclusions:
Clinicians
consider
early
normal
weight,
overweight,
avoid
those
subjects
ae
underweight,
anorexic,
malnourished.
Cells,
Journal Year:
2025,
Volume and Issue:
14(9), P. 668 - 668
Published: May 2, 2025
Sodium-glucose
cotransporter-2
inhibitors
(SGLT2i)
are
currently
recommended
in
patients
with
type
2
diabetes
(T2D)
to
reduce
serum
glucose
levels.
Moreover,
robust
evidence
has
clearly
demonstrated
their
beneficial
cardiovascular
and
renal
effects,
making
this
class
of
drugs
pivotal
for
the
treatment
T2D,
especially
when
complicated
by
diabetic
kidney
disease
or
heart
failure.
However,
several
other
comorbidities
frequently
encountered
T2D
beyond
these
long-term
complications,
internal
medicine
setting.
For
some
comorbidities,
such
as
MAFLD
cognitive
impairment,
association
is
increasingly
recognized,
hypothesis
a
common
pathophysiologic
background,
whereas,
others,
coincident
epidemiology
linked
ageing
populations,
including
that
subjects,
may
be
advocated.
In
effort
personalizing
treatment,
on
potential
effects
SGLT2i
different
clinical
conditions
accumulating.
The
purpose
narrative
review
update
current
literature
settings
glycaemic
control,
elucidate
molecular
mechanisms
which
they
exert
effects.
npj Aging,
Journal Year:
2025,
Volume and Issue:
11(1)
Published: May 10, 2025
Abstract
Cellular
senescence
is
the
permanent
cessation
of
cell
proliferation
and
growth.
Senescent
cells
accumulating
in
tissues
organs
with
aging
contribute
to
many
chronic
diseases,
mainly
through
secretion
a
pro-inflammatory
senescence-associated
secretory
phenotype
(SASP).
Senotherapeutic
(senolytic
or
senomorphic)
strategies
targeting
senescent
or/and
their
SASP
are
being
developed
prolong
healthy
lifespan
treat
age-related
pathologies.
Sodium-glucose
co-transporter
2
(SGLT2)
inhibitors
new
class
anti-diabetic
drugs
that
promote
renal
excretion
glucose,
resulting
lower
blood
glucose
levels.
Beyond
glucose-lowering
effects,
SGLT2
have
demonstrated
protective
effects
against
cardiovascular
events.
Moreover,
recently
been
associated
inhibition
senescence,
making
them
promising
therapeutic
approach
for
aging.
This
review
examines
latest
research
on
senotherapeutic
potential
inhibitors.
Diabetes Obesity and Metabolism,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 10, 2024
Abstract
Sodium‐glucose
cotransporter
2
(SGLT2)
inhibitors,
originally
designed
to
manage
blood
sugar
levels
in
individuals
with
type
diabetes
(T2D),
have
emerged
as
a
crucial
class
of
drugs
for
managing
cardio‐renal
diseases.
These
work
by
targeting
the
SGLT2
protein
kidneys,
promoting
excretion
glucose
and
influencing
metabolic
pathways
beyond
control.
The
relationship
between
diseases
inhibitors
has
been
explored
through
landmark
trials
real‐world
evidence
(RWE)
studies,
demonstrating
significant
reductions
complications.
This
review
discusses
importance
RWE
studies
alongside
randomized
controlled
understanding
effectiveness
safety
inhibitors.
It
outlines
advantages
disadvantages
compared
RCTs,
highlighting
their
complementary
roles
providing
comprehensive
insights
into
treatment
outcomes.
By
examining
range
underscores
benefits
across
various
patient
populations.
Safety
assessments
indicate
that
are
generally
well
tolerated,
severe
adverse
events
being
rare.
Common
issues,
such
genital
mycotic
infections
urinary
tract
infections,
acknowledged,
less
frequent
but
including
diabetic
ketoacidosis,
lower‐limb
amputations,
bone
fractures.
In
summary,
show
promising
protective
effects
scenarios
diverse
populations
T2D,
indicating
potential
early
intervention
measures.
Continued
research
is
essential
gaining
thorough
long‐term
profiles.
